Skip to main content

ANI launches benztropine mesylate tablets


BAUDETTE, Minn. — ANI Pharmaceuticals has launched its benztropine mesylate tablets, the company announced Tuesday. The drug is the tenth commercial introduction the company has seen in 2016, according to CEO Arthur Przybyl. 


ANI’s benztropine mesylate tablets will be available in 0.5-, 1-, and 2-mg dosage strengths. The product has a current market size of about $25 million, according to IMS Health data. 


This ad will auto-close in 10 seconds